Clinical & Experimental Metastasis

, Volume 25, Issue 2, pp 139–148 | Cite as

CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

  • Qiming Chen
  • Carol D. Manning
  • Hillary Millar
  • Francis L. McCabe
  • Catherine Ferrante
  • Celia Sharp
  • Lillian Shahied-Arruda
  • Parul Doshi
  • Marian T. Nakada
  • G. Mark Anderson
Research Paper


CNTO 95 is a fully human monoclonal antibody that recognizes αv integrins. Previous studies have shown that CNTO 95 exhibits both anti-tumor and anti-angiogenic activities (Trikha M et al., Int J Cancer 110:326–335, 2004). In this study we investigated the biological activities of CNTO 95 on breast tumor cells both in vitro and in vivo. In vitro treatment with CNTO 95 decreased the viability of breast tumor cells adhering to vitronectin. CNTO 95 inhibited tumor cell adhesion, migration, and invasion in vitro. CNTO 95 treatment also induced tyrosine dephosphorylation of focal adhesion kinase (FAK), and the docking protein paxillin that recruits both structural and signaling molecules to focal adhesions (Turner CE, Int J Biochem Cell Biol 30:955–959, 1998; O’Neil GM et al., Trends Cell Biol 10:111–119, 2000). These results suggest that CNTO 95 inhibits breast tumor cell growth, migration and invasion by interruption of αv integrin mediated focal adhesions and cell motility signals. In vivo studies of CNTO 95 were conducted in an orthotopic breast tumor xenograft model. Treatment with CNTO 95 resulted in significant inhibition of both tumor growth and spontaneous metastasis of MDA-MB-231 cells to the lungs. CNTO 95 also inhibited lung metastasis in a separate experimental (tail vein injection) model of metastasis. The results presented here demonstrate the anti-tumor and anti-metastatic activities of CNTO 95 in breast cancer models and provide insight into the cellular and molecular mechanisms mediating its inhibitory effects on metastasis.


CNTO 95 αv integrin Cell migration Cell invasion MCF-7 MDA-MB-231 MDA-MB-468 MX-1 Breast cancer Focal adhesion kinase Paxillin Lung metastasis 



We thank Paul Marsters for his help in statistical analysis and Ray Heslip for his help preparing graphs.


  1. 1.
    Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673–687PubMedCrossRefGoogle Scholar
  2. 2.
    Juliano RL, Reddig P, Alahari S, Edin M, Howe A, Aplin A (2004) Integrin regulation of cell signalling and motility. Biochem Soc Trans 32:443–446PubMedCrossRefGoogle Scholar
  3. 3.
    Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S (2000) Differential clinical significance of alpha(v) Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer 89:153–159PubMedCrossRefGoogle Scholar
  4. 4.
    Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y (2000) Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 7:19–26PubMedCrossRefGoogle Scholar
  5. 5.
    Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA (2001) Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumor 87:173–178Google Scholar
  6. 6.
    Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J (2001) Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res 7:4073–4079PubMedGoogle Scholar
  7. 7.
    Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, Oda Y (2003) Expression of alphav integrin family in gastric carcinomas: increased alphavbeta6 is associated with lymph node metastasis. Pathol Res Pract 199:57–64PubMedCrossRefGoogle Scholar
  8. 8.
    Sato T, Konishi K, Maeda K, Yabushita K, Miwa A (2003) Integrin alpha v, c-erbB2 and DNA ploidy in lung metastases from colorectal cancer. Hepatogastroenterology 50:27–30PubMedGoogle Scholar
  9. 9.
    Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4:191–194PubMedCrossRefGoogle Scholar
  10. 10.
    Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Hofler H, Schmitt M, Reuning U (2003) Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem 384:1073–1083PubMedCrossRefGoogle Scholar
  11. 11.
    Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207–238PubMedCrossRefGoogle Scholar
  12. 12.
    Wittekind C, Neid M (2005) Cancer invasion and metastasis. Oncology 69(Suppl 1):14–16PubMedCrossRefGoogle Scholar
  13. 13.
    Bartsch JE, Staren ED, Appert HE (2003) Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res 110:287–294PubMedCrossRefGoogle Scholar
  14. 14.
    Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, Tanghetti E, Dammacco F (2001) Alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 29:993–1003PubMedCrossRefGoogle Scholar
  15. 15.
    Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409–1416PubMedCrossRefGoogle Scholar
  16. 16.
    Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA (2000) Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19:5606–5613PubMedCrossRefGoogle Scholar
  17. 17.
    Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68PubMedCrossRefGoogle Scholar
  18. 18.
    Turner CE (2000) Paxillin interactions. J Cell Sci 113(Pt 23):4139–4140PubMedGoogle Scholar
  19. 19.
    Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT (2004) CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 110:326–335PubMedCrossRefGoogle Scholar
  20. 20.
    Veryard C (2006) AACR-NCI-EORTC–17th symposium: molecular targets and cancer therapeutics. 14–18th November 2005, Philadelphia, PA, USA. IDrugs 9:1–3PubMedGoogle Scholar
  21. 21.
    Atienza JM, Zhu J, Wang X, Xu X, Abassi Y (2005) Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 10:795–805PubMedCrossRefGoogle Scholar
  22. 22.
    Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100PubMedCrossRefGoogle Scholar
  23. 23.
    Aznavoorian S, Stracke ML, Parsons J, McClanahan J, Liotta LA (1996) Integrin alphavbeta3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways. J Biol Chem 271:3247–3254PubMedCrossRefGoogle Scholar
  24. 24.
    Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH (2001) Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 12:2699–2710PubMedGoogle Scholar
  25. 25.
    Frame MC (2004) Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117:989–998PubMedCrossRefGoogle Scholar
  26. 26.
    Turner CE (1998) Paxillin. Int J Biochem Cell Biol 30:955–959PubMedCrossRefGoogle Scholar
  27. 27.
    O’Neill GM, Fashena SJ, Golemis EA (2000) Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 10:111–119PubMedCrossRefGoogle Scholar
  28. 28.
    Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77–102PubMedGoogle Scholar
  29. 29.
    Price JE, Polyzos A, Zhang RD, Daniels LM (1990) Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 50:717–721PubMedGoogle Scholar
  30. 30.
    Tucker GC (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8:96–103PubMedCrossRefGoogle Scholar
  31. 31.
    Hanks SK, Ryzhova L, Shin NY, Brabek J (2003) Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 8:d982–d996PubMedCrossRefGoogle Scholar
  32. 32.
    Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, Hershey ED, Beggs HE, Reichardt LF, Parsons JT (2005) Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci 118:2613–2623PubMedCrossRefGoogle Scholar
  33. 33.
    Brown MC, Cary LA, Jamieson JS, Cooper JA, Turner CE (2005) Src and FAK kinases cooperate to phosphorylate paxillin kinase linker, stimulate its focal adhesion localization, and regulate cell spreading and protrusiveness. Mol Biol Cell 16:4316–4328PubMedCrossRefGoogle Scholar
  34. 34.
    Cohen LA, Guan JL (2005) Mechanisms of focal adhesion kinase regulation. Curr Cancer Drug Targets 5:629–643PubMedCrossRefGoogle Scholar
  35. 35.
    McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5:505–515PubMedCrossRefGoogle Scholar
  36. 36.
    Sein TT, Thant AA, Hiraiwa Y, Amin AR, Sohara Y, Liu Y, Matsuda S, Yamamoto T, Hamaguchi M (2000) A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9. Oncogene 19:5539–5542PubMedCrossRefGoogle Scholar
  37. 37.
    Schaller MD (2004) FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration? J Cell Biol 166:157–159PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Qiming Chen
    • 1
  • Carol D. Manning
    • 1
  • Hillary Millar
    • 1
  • Francis L. McCabe
    • 1
  • Catherine Ferrante
    • 1
  • Celia Sharp
    • 1
  • Lillian Shahied-Arruda
    • 1
  • Parul Doshi
    • 1
  • Marian T. Nakada
    • 1
  • G. Mark Anderson
    • 1
  1. 1.Oncology ResearchCentocor R&D, Inc.RadnorUSA

Personalised recommendations